(MedPage Today) — Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) with a progressive pulmonary fibrosis phenotype, the phase III FIBRONEER-ILD…
Source link : https://www.medpagetoday.com/meetingcoverage/ats/115651
Author :
Publish date : 2025-05-19 16:17:00
Copyright for syndicated content belongs to the linked Source.
